Table 3.

Duration of dupilumab exposure by dose in patients who switched from qw to q2w^a

Patients with treatment exposure, weeks	Dupilumab dose (N = 226)
	Overall exposure (300 mg qw or q2w)	300 mg qw	300 mg q2w
1 to <4	0	0	0
4 to <12	0	0	1 (0.4)
12 to <16	0	0	1 (0.4)
16 to <24	0	0	2 (0.9)
24 to <52	0	0	175 (77.4)
52 to <76	0	0	47 (20.8)
76 to <156	0	0	0
156 to <182	0	67 (29.6)	0
182 to <208	5 (2.2)	99 (43.8)	0
208 to <234	70 (31.0)	56 (24.8)	0
234 to <260	112 (49.6)	4 (1.8)	0
≥260	39 (17.3)	0	0

Data are expressed as n (%) unless otherwise specified

q2w every 2 weeks, qw weekly

^aPatients transitioned from dupilumab qw to q2w following Protocol Amendment 9